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The generally accepted mechanism of allergy is still that it depends pre-
dominantly on the presence of histamine or chemically similar substance in ab-
normal quantities in the affected tissues, or an unusual and unexplained sensi-
tivity to histamine. This activity is specific for histamine in that it requires the




Similar compounds not containing this molecular configuration are devoid of
histamine activity.
For obvious reasons it is not only impossible but impractical to check histamine
formation. Almost a quarter century ago attempts were initiated to make avail-
able an antagonist which would either successfully combat formation of histamine
or nullify its effects. This presented many difficulties. Naturally, attention was
first directed to the sympathomimetic drugs such as epinephrin, but since these
substances do not prevent the capillary dilatation induced by histamine, they
were discarded.
In 1953 Rothlin and Cerletti (1), and Huber (2) evaluated a new antihistaminic
drug, designated Sandostene. Chemically this is 1-methyl-4-amino-N'-phenyl-N'
(2'-thenyl)-piperidine-tartrate.
Rothlin and Cerletti combined this substance with calcium for intravenous
administration. The logic of this combination was based on experimental and
clinical experience which followed the use of calcium with various other anti-
histaminic drugs. There was some apparent synergism with benefits not obtain-
able from either substance alone. While calcium is by no means an antihistaminic
it does have a decongestive effect. Calcium also exerts a sedative effect on the
cortical sensory centers, the medulla and spinal cord. Combining an antihista-
minic with calcium seemed to offer advantages over each substance individually,
but the clinical substantiation was still to be demonstrated.
Many antihistaminics inhibit acetylcholine; some, however in doses far beyond
their therapeutic range. Since acetylcholine seems to play a role in allergic re-
actions and may even participate in development of vegetative disturbances
associated with allergy, some anticholinergic action would be desirable.
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The same investigators concluded that Sandostene possesses great anti-
histaminic activity as well as anticholinergic activity, local anesthetic properties,
plus antipermeability properties.
In the fall of 1953 we undertook a clinical evaluation of Sandostene by mouth,
alone, and combined with calcium gluconogalactogluconate intravenously, in
order to determine the effects on pruritus, insomnia due to pruritus, and the
decongestive effect in inflammatory processes, many of an allergic nature. To
facilitate control of patients it was deemed advisable to conduct this study on
private patients. This principle was adhered to with the exception of several
hospitalized patients who received intravenous medication.
METHOD
One hundred thirty five patients were included in this study, twenty five of
whom received intravenous injections of Sandostene plus Neocaiglucon (calcium
gluconogalactogluconate). Patients were not grouped according to the dermatoses
from which they suffered; nor was any attempt made to classify them in homol-
ogous groups with respect to age, sex, severity or duration of the disease. The
reason for this was that the action of both medications was essentially empiric;
evaluation of effects was based on subjective and objective evidence of sympto-
matic relief, the former especially as it related to insominia and pruritus.
All patients, as far as could be determined, were apparently in good health
except for their dermatoses.
The latter included over two dozen various dermatoses associated with itching
which interfered with the patient's normal activity and with sleep. In a few
dermatoses the purpose of administration was to overcome anxiety and stress.
Sandostene was given in compressed tablets, each containing 25 mgm. of the
active ingredient; dosages varied daily from 75 to 250 mgm. The maximum total
dosage was 43.2 grams (approximately 250 mgm. daily), over a six month eri od.
Those patients treated intravenously received 10 cc containing 1.375 gm. of
calcium gluconogalactogluconate plus 0.05 gm. of Sandostene.
One patient received intravenous medication once daily for 37 days.
RESULTS WITH COMMENT
No adverse effects were noted in urinary findings or hemograms of any patient.
Icterus indices were not altered.
Both parenteral and oral medication exhibited antihistaminie and sedative
effects. The latter were not apparent from the mouth medication when only one
or two tablets were given. However three tablets caused drowsiness, even during
daytime hours of normal activity. After intravenous medication sedation was
quite noticeable; ambulatory patients were advised to abstain from driving
automobiles for two hours after medication. In many instances intravenous
medicatioii given as early in the day as noon was followed by a restful night and
freedom from pruritus. In general, sedation and relief from pruritus lasted for
from six to eight hours after injection. One thin, elderly woman (aged 75 years)
experienced a brief attack of syncope a half hour after receiving 10 cc of the
intravenous medication. It is advisable to give smaller doses in the elderly.
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The relief from pruritus did not seem due to any evident cortical sedation
as there was no complaint of drowsiness after the oral medication, although the
itch reflex was partially or completely abolished. On the contrary this relief from
pruritus did not seem wholly dependent on any decongestant effect, as urticarial
lesions would persist although the pruritus had subsided.
Best results were obtained in disseminate neurodermatitis (atopic eczema),
and contact dermatitis, especially of the generalized type. Many of the atopics
had associated hay-fever and/or asthma. These \vere in general relieved.
Clinicians are at present evaluating the limitations of cortisone and adreno-
corticotropic hormone in the treatment of the stress syndrome associated with
tissue injury. While response to these is quite dramatic, they have side reactions
and contraiudications which, if not respected, may endanger life. There are
certain similarities between the activity of these substances and the antihista-
minics. When cells are injured there is consequent inflammation and release
from the injured cell of histamine and histamine-like compounds which flood
the entire organism. These substances are considered by many to be the actual
cause of systemic toxicity ("histamine shock syndrome"). Similar histamine
response follows allergic shock and many instances of drug reactions due to
idiosyncrasy to dose. Many instances of dermatitis medicamentosa respond
dramatically to cortisone. The response to an effective antihistaminic, especially
when given by intravenous injection with calcium is sometimes equally dramatic.
Three of our patients had better results from Sandostene than from hormonal
therapy of their allergy. In the more protracted allergies, such as chronic urti-
caria, atopic dermatitis and asthma, calcium and Sandostene are preferred; and
while not regnlarly as prompt in effect, are after several weeks of administration,
more effective and free of any side effects and toxicity.
The antihistaminics act directly on histamine as antagonists, thus neutralizing
its toxicity to tissues and relieving in whole or in part objectionable subjective
and objective symptoms. Adrenocorticotropic hormone and cortisone have no
effect on itching per se; they only relieve it indirectly by overcoming systemic
and local tissue stress.
SUMMARY AND CONCLUSIONS






2. Sandostene plus Neoealglucon was administered intravenously to 25 sub-
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3. Side actions consisted of one case of cramps and diarrhea a half hour after
ingestion of each tablet. Drowsiness followed more than two tablets by mouth
and all instances of intravenous medication.
4. No instance of toxicity was encountered.
5. The incidence of side effects was lower thall that reported with equivalent
doses of other histamine antagonists at present in general use.
6. The combination of Neocaiglucon and Sandostene as used in this study
seems to be low in toxicity and highly suitable to supplement and widen the
therapeutic range of calcium. The combination is well tolerated and possesses
high antipermeability action resulting in manifold therapeutic effects which
favor its use in treatment of the protean manifestations of allergic disease of the
skin.
The material for conducting this investigation was supplied by Sandoz Pharmaceuticals,
Division of Sandoz Chemical Works, Inc.
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